Covid: Moderna, ‘vaccine in 12-18 year olds 100% effective and safe’

Milan, May 25 (beraking latest news Health) – Moderna’s anti-Covid vaccine shows 100% effectiveness in 12-18 year olds. And in this age group, “no significant safety issues” are encountered. This is what the US pharmaceutical company announces by communicating that the phase 2/3 TeenCOVE study on its vaccine (mRNA-1273) for adolescents reaches the primary endpoint of immunogenicity not lower than that of the adult comparison group of the phase study 3.

High protection data are found already after the first shield injection, reports Moderna. Using the case definition of the Center for Disease Control and Prevention (Cdc), a vaccine efficacy of 93% was observed after the first dose. After the two doses, no cases of Covid-19 were observed, using the primary case definition. And this result is consistent with a vaccine efficacy of 100%.

The TeenCOVE study enrolled more than 3,700 participants between the ages of 12 and 18 in the United States.

93% efficacy was observed starting 14 days after the first dose. While at the completed course, after two doses, no cases were observed in the group of participants receiving the vaccine, compared to 4 reported in the placebo group, with a vaccine efficacy of 100% starting 14 days after the second injection.

Since the incidence rate of Covid-19 is lower in adolescents, the Cdc case definition was also evaluated to include those presenting with milder symptoms. The vaccine, Moderna reports, was generally well tolerated with a safety and tolerability profile generally consistent with the Phase 3 Cove study in adults. The “majority of adverse events were mild or moderate in severity”. The most common were pain at the injection site and after the second dose headache, fatigue, myalgia and chills.

The company explains that safety data is continuing to accumulate and the study continues to be monitored by an independent committee. All participants will be followed up for 12 months after their second injection, with the aim of evaluating the long-term protection and safety of the vaccine. Moderna plans to submit data from the TeenCove study for peer-reviewed publication.